Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Dec;11(4):355-60.
doi: 10.1016/j.aju.2013.08.014. Epub 2013 Oct 20.

The role of an abnormal prostate-specific antigen level and an abnormal digital rectal examination in the diagnosis of prostate cancer: A cross-sectional study in Qatar

Khalid Al Rumaihi  1 , Khalid Al Jalham  1 , Nagy Younes  1 , Ahmad A Majzoub  1 , Ahmed A Shokeir  2
Affiliations

The role of an abnormal prostate-specific antigen level and an abnormal digital rectal examination in the diagnosis of prostate cancer: A cross-sectional study in Qatar

Khalid Al Rumaihi et al. Arab J Urol. 2013 Dec.

Abstract

Objective: To investigate the role of an abnormal prostate-specific antigen (PSA) level and abnormal findings on a digital rectal examination (DRE) in the detection of prostate cancer in men in Qatar.

Patients and methods: Between June 2008 and September 2012, 651 patients had a transrectal ultrasonography-guided biopsy of the prostate (TRUSBP) at our centre. The indications for a biopsy were a high PSA level (>4 ng/mL), or an abnormal DRE result. Patients were assessed by a thorough history, clinical examination and routine laboratory investigations. Data, including age, DRE findings, TRUS findings, total PSA level, prostate volume and the pathology results, were evaluated.

Results: The mean (SD) age of the 651 patients was 64.1 (7.4) years. Prostate cancer was detected in 181 men (27.8%), benign prostatic hyperplasia in 275 (42.2%) and prostatitis in 236 (36.4%). The sensitivity and specificity for detecting prostate cancer were 93.9% and 8.5% for an abnormal PSA level (>4 ng/mL), 46.1% and 84.7% for abnormal DRE findings, and 95% and 30.2% for the two combined. Using a receiver operating characteristics curve, a PSA threshold of 7.9 ng/mL had a sensitivity of 56.6% and specificity of 52.8%. When a PSA threshold of 7.9 ng/mL was used in combination with abnormal DRE findings, the overall accuracy was 76.9%.

Conclusion: The PSA threshold level of 7.9 ng/mL, determined by this analysis, has a higher likelihood of detecting prostate cancer in men in Qatar. However, it failed to detect cancer in substantially many men with statistically significant disease.

Keywords: Biopsy; NPV, negative predictive value; PPV, positive predictive value; PSA; Prostate cancer; ROC, receiver operating characteristics (curve); TRUSBP, TRUS-guided prostate biopsy; Transrectal ultrasonography.

PubMed Disclaimer

Figures

Figure 1
Figure 1
ROC curve for total PSA level against the incidence of prostate cancer. The area under the curve was 0.638.
None
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96. - PubMed
    1. Heidenreich APJ, Bastian J, Bellmunt M, Bolla S, Joniau MD, Mason V, et al. The updated EAU Guidelines on Prostate Cancer. 2012. Available at <http://www.uroweb.org/gls/pdf/08%20Prostate%20Cancer_LR%20March%2013th%2...>.
    1. Breslow N., Chan C.W., Dhom G., Drury R.A., Franks L.M., Gellei B. Latent carcinoma of prostate at autopsy in seven areas. The International agency for research on cancer, Lyons, France. Int J Cancer. 1977;15:680–688. - PubMed
    1. Heidenreich AP, Aus G, Abbou CC, Bolla M, Joniau S, Matveev V, et al. Guidelines on Prostate Cancer. European Association of Urology 2007: 7–9 Available at <http://www.uroweb.org/fileadmin/user_upload/Guidelines/Prostate%20Cancer...>.
    1. Quinn M., Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I. International comparisons. BJU Int. 2002;90:162–173. - PubMed